Each gram of cream contains Clobetasol (as propionate) 500 mcg (0.05% w/w).
Clobetasol propionate is of particular value when used in short courses for the treatment of more resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas and other conditions which do not respond satisfactorily to less active steroids.
A small quantity should be applied to the affected area once or twice daily until improvement occurs. Therapy should be discontinued when control is achieved. It is recommended that treatment should not be continued for more than two or four weeks without the patient's condition being reviewed. If continuous steroid treatment is required, a less potent preparation is required.
Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse, the features of hypercorticism may appear and in this situation, topical steroids should be discontinued.
Rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritis. Primary cutaneous viral infections (eg, Herpes simplex, chickenpox). Hypersensitivity to the preparation, dermatoses in children <1 year of age including dermatitis and napkin eruptions.
Long term therapy should be avoided, particularly in infants and children as adrenal suppression can occur even without occlusion. If Clobetasol is required for use in children, it is recommended that the treatment should be reviewed weekly. It should be noted that the infant's napkin may act as an occlusive dressing.
The face, more than any other areas in the body may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids.
If applied to the eyelids, care is needed to ensure that Clobetasol does not enter the eye as glaucoma might result. Topical steroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerance, risk of generalized pustular psoriaris for a number of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis, careful patient supervision is important.
Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and systemic administration of antimicrobial agents.
Topical administration of corticosteroids in pregnant animals can cause abnormalities of fetal development. The relevance of this finding to human beings has not been established, however, topical steroids should not be used extensively in pregnancy i.e., in large amounts or for prolonged periods.
Skin atrophy especially with occlusion or in skin folds, hypercorticism. Provided the weekly dosage is less than 50 g in adults, any pituitary-adrenal suppression is likely to be transient. Occasional hypersensitivity may occur.
Store at temperatures not exceeding 30°C. Protect from light.
D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.